Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 7 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Seattle Children's Hospital (dba Seattle Children's Research Institute) has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 examiners and 8 art units, showing broad examiner distribution with more limited art-unit distribution. Counsel needs centralized docket control and coordinated technical support, while allowing individual office actions to determine claim and prior-art strategy.
NGUYEN, QUANG is the busiest examiner, with 2 pending matters. The remaining actions are handled by other examiners, and the art-unit structure does not mirror the examiner distribution. Counsel should review the two matters assigned to this examiner together for consistency, while managing the other files through their own examination records.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 2 | 37.9% | +52.6% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336248 | METHOD FOR TREATING AUTOIMMUNE DISEASE USING CD4 T-CELLS WITH ENGINEERED STABILIZATION OF EXPRESSION OF ENDOGENOUS FOXP3 GENE | CUNNINGCHEN, KATHLEEN MARY | 26d |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | HAMA, JOANNE | 28d |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | NGUYEN, QUANG | 157d overdue |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | BATES, KEENAN ALEXANDER | 147d overdue |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | HUYNH, PHUONG N | 16d overdue |
| 18336248 | METHOD FOR TREATING AUTOIMMUNE DISEASE USING CD4 T-CELLS WITH ENGINEERED STABILIZATION OF EXPRESSION OF ENDOGENOUS FOXP3 GENE | CUNNINGCHEN, KATHLEEN MARY | 26d |
| 17811685 | LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID | PYLA, EVELYN Y | 27d |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | HAMA, JOANNE | 28d |
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | — |
| 18030476 | METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES | JONES-FOSTER, ERICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1631 | 4 |
| 1646 | 1 |
| 1656 | 1 |
| 1647 | 1 |
| 1641 | 1 |
| 1633 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18441393 | ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS | GRABER, JAMES J | 1631 | §102§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18336248 | METHOD FOR TREATING AUTOIMMUNE DISEASE USING CD4 T-CELLS WITH ENGINEERED STABILIZATION OF EXPRESSION OF ENDOGENOUS FOXP3 GENE | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112 | Final Rejection | 26d | Pending | Jun 16, 2023 |
| 18336276 | EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS | NGUYEN, QUANG | 1631 | §103DP | Non-Final OA | 157d overdue | Pending | Jun 16, 2023 |
| 18030476 | METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | HAMA, JOANNE | 1647 | §103§112 | Non-Final OA | 28d | Pending | Dec 01, 2022 |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | HUYNH, PHUONG N | 1641 | DP | Final Rejection | 16d overdue | Pending | Sep 12, 2022 |
| 17811685 | LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID | PYLA, EVELYN Y | 1633 | §103 | Final Rejection | 27d | Pending | Jul 11, 2022 |
| 17424140 | MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | 147d overdue | Pending | Jul 19, 2021 |
| 17050601 | THERAPEUTIC GENOME EDITING IN X-LINKED HYPER IGM SYNDROME | MARVICH, MARIA | 1634 | §112 | Final Rejection | — | Pending | Oct 26, 2020 |
| 16605740 | OPTIMIZED LENTIVIRAL VECTOR FOR XLA GENE THERAPY | NGUYEN, QUANG | 1631 | §112 | Final Rejection | — | Pending | Oct 16, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeattle Children's Hospital (dba Seattle Children's Research Institute) has 10 pending office actions as of October 2026, spread across 7 art units and 9 examiners.
Quang Nguyen has the most, with 2 of Seattle Children's Hospital (dba Seattle Children's Research Institute)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
